or Try an Advanced Search...

    Holdings

    Symbol Grade Price % Change Allocation
    NVS D 0.88 2.01
    UL D 0.67 2.00
    DEO F 0.04 1.95

    Represented by ETF Holdings

    Keywords: Active Pharmaceutical Ingredients Alcohol Alcoholic Drinks Animal Health Antibiotics Beer Biotechnology Blood Test Canadian Whisky Cleaning Products Contact Lens Contact Lenses Deodorant Diagnostic Products Disposable Product Disposable Products Distilled Drinks Drink Drugs Eye
    Industries: Beverages - Wineries & Distilleries Drug Manufacturers - Major Household & Personal Products

    Recent News for First Trust International Developed Cap Strength ETF & its Holdings

    Date Stock Title
    Nov 1 NVS Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus
    Nov 1 DEO TEQUILA DON JULIO ELEVATES MEXICO'S CULTURAL HERITAGE WITH BREATHTAKING DIA DE MUERTOS GLOBAL CELEBRATIONS
    Nov 1 NVS Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up
    Nov 1 NVS Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
    Oct 31 DEO Aged to Perfection: Crown Royal Launches Iconic Reserve Offering with 12-Year Age Statement
    Oct 31 NVS REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales
    Oct 30 NVS Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
    Oct 30 DEO Ketel One Family Made Vodka Taps Patrick Schwarzenegger to Serve as First Ever "Spirit Advisor" this Holiday Season
    Oct 30 NVS Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks
    Oct 30 NVS BioMarin Q3 Earnings & Revenues Beat Estimates, '24 Guidance Raised
    Oct 30 NVS ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
    Oct 30 NVS Novartis’ Scemblix gains FDA approval for leukaemia
    Oct 30 NVS Novartis: It's Not Too Late To Buy This Dividend Stock Now
    Oct 30 NVS Novartis Reports Strong Q3 Growth and Raises Guidance
    Oct 30 NVS Novartis AG (NVS) Q3 2024 Earnings Call Highlights: Record Cash Flow and Robust Sales Growth
    Oct 29 NVS Novartis: Strong Financials, But Market Skepticism Persists Amid Pipeline Concerns
    Oct 29 NVS Novartis wins first-line chronic myeloid leukemia indication for Scemblix
    Oct 29 NVS Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
    Oct 29 NVS Novartis Stock Dives on $800 Million Write-Down
    Oct 29 NVS Novartis Ag (NVS) Q3 2024 Earnings Call Transcript
    The investment seeks investment results that correspond generally to the price and yield of an index called The International Developed Capital Strength IndexSM. The fund seeks to achieve its investment objective by investing, under normal market conditions, at least 90% of its net assets in the common stocks and REITs that comprise the index. The index seeks to provide exposure to well-capitalized companies in the developed markets outside of the U.S. with strong market positions that have the potential to provide their stockholders with a greater degree of stability and performance over time. The fund is non-diversified.
    Exchange Traded Fund Index Fund Investment Management Real Estate Investment Trust
    Back to the Main FICS Page...